Malignant Neoplasm of Unknown Primary

In a comparison of 6 renal medullary carcinomas (RMC) and 22 collecting duct carcinomas (CDC), all 6 RMC were negative for SMARCB1 by IHC whereas only 1 of 22 CDC lost SMARCB1 expressing, supporting S… (full text at CIViC)

PMID 22686875 · Calderaro et al., 2012 · Open in CIViC

The correlation between FGFR2/SPRY2 and clinicopathologic factors was analyzed by Chi-square to screen the FGFR2/SPRY2-relevant factors. SPRY2 low expression was demonstrated to be significantly assoc… (full text at CIViC)

PMID 28002800 · Xu et al., 2017 · Open in CIViC

Drilon et al (2022) assessed the efficacy and safety of larotrectinib in lung cancer patients with TRK fusions in a phase II adult/young adult trial (NCT02576431) and a phase I adult trial (NCT0212291… (full text at CIViC)

PMID 35085007 · Drilon et al., 2022 · Open in CIViC

Bragas et al (2022) report a case study of a 50-year old female with a papillary thyroid carcinoma with multiple metastases containing a SQSTM1::NTRK1 fusion treated with larotrectinib. SQSTM1::NTRK1 … (full text at CIViC)

PMID 35118995 · Bargas et al., 2022 · Open in CIViC

Phase II study of pasireotide in metastatic neuroendocrine tumours enrolled 29 patients. Overall median PFS was 11 months (95% CI, 7.6–16 months). High SSTR5 expression (seen in 17/22 samples measured… (full text at CIViC)

PMID 25376618 · Cives et al., 2015 · Open in CIViC

In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC)

PMID 38461159 · Zhang et al., 2024 · Open in CIViC

In a retrospective analysis in two separate datasets (Stand Up To Cancer 2 Cohort and Checkmate-057), patients with concomitant KRAS and STK11 mutations had significantly worse response rates, PFS and… (full text at CIViC)

PMID 29773717 · Skoulidis et al., 2018 · Open in CIViC

Patients with metastatic colorectal cancer with STRN-ALK fusion, sporadic microsatellite instability high (MSI-H) and KRAS R164Q received ALK inhibitor ceritinib. After pts received ceritinib perinumb… (full text at CIViC)

PMID 26933125 · Yakirevich et al., 2016 · Open in CIViC

TROP2 T256R mutation alters the plasma membrane localization and cell-surface binding of hRS7, the humanized antibody incorporated into Sacituzumab Govitecan (SG). The TROP2 T256R encoded protein was … (full text at CIViC)

PMID 34404686 · Coates et al., 2021 · Open in CIViC

In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no muta… (full text at CIViC)

PMID 25024077 · Xing et al., 2014 · Open in CIViC

A total of 96 histopathologically confirmed RCC cases and corresponding normal tissues were subjected to hTERT gene expression using real-time PCR. Two RCC cell lines viz. ACHN and A498 were treated w… (full text at CIViC)

PMID 28215740 · Pal et al., 2017 · Open in CIViC

This study evaluates 200 nephrectomy cases. Within the 200 cases, there are four cases that are Xp11.2 translocation renal cell carcinomas (RCC). Previous studies identified two stages (pediatric and … (full text at CIViC)

PMID 34917511 · Ge et al., 2021 · Open in CIViC

This manuscript is a study of 37 TFEB-altered tumors, 15 of which are associated with TFEB amplification at 6p21.1 and 22 of which are associated with TFEB-rearrangement. Previous literature had indic… (full text at CIViC)

PMID 31600176 · Gupta et al., 2019 · Open in CIViC

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

This study evaluated genomic biomarkers associated with treatment response and clinical outcomes in patients with locally advanced rectal adenocarcinoma (LARC) treated with neoadjuvant chemoradiation … (full text at CIViC)

PMID 37260182 · Lee et al., 2023 · Open in CIViC

In a single-center observational study of 102 patients with microsatellite stable (MSS) metastatic colon cancer receiving standard treatments, high tumor mutational burden (TMB ≥10 mutations/Mb) was a… (full text at CIViC)

PMID 39639373 · Di Mauro et al., 2024 · Open in CIViC

This is part of the randomised double-blind phase 3 trial, CameL-sq, a study that assessed the therapeutic effectiveness of the PD-1 blockade, camrelizumab plus chemotherapy as first-line treatment in… (full text at CIViC)

PMID 34980131 · Jiang et al., 2022 · Open in CIViC

TOP1 E418K mutation and TOP1 122fs contribute to acquired resistance to Sacituzumab Govitecan (SG) therapy through alterations in the drug target TOP1. The patient, a 42-year-old female with metastati… (full text at CIViC)

PMID 34404686 · Coates et al., 2021 · Open in CIViC

In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those witho… (full text at CIViC)

PMID 22090360 · Skinner et al., 2012 · Open in CIViC

Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC)

PMID 12509970 · Yamazaki et al., 2003 · Open in CIViC

In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.

PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC

Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with … (full text at CIViC)

PMID 11325447 · Alsner et al., 2001 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

As seen in Figure 1, the R213* mutation is predominantly found in colorectal and breast cancers. The variant was described as being a frequent p53 nonsense mutation in melanoma, kidney chromophobe, es… (full text at CIViC)

PMID 28249646 · Panaccione et al., 2017 · Open in CIViC

In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients.

PMID 21467160 · Lindenbergh-van der Plas et al., 2011 · Open in CIViC

In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate ana… (full text at CIViC)

PMID 21467160 · Lindenbergh-van der Plas et al., 2011 · Open in CIViC

Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC)

PMID 30833958 · Deng et al., 2019 · Open in CIViC

A healthy 12 year old with right neck mass was found to have heterogeneous solid mass originating from the right thyroid lobe. Total thyroidectomy confirmed papillary thyroid carcinoma (PTC) with mult… (full text at CIViC)

PMID 29610391 · Ronsley et al., 2018 · Open in CIViC

FFPE samples from 351 primary thyroid carcinomas were subjected to targeted gene rearrangement next-generation sequencing, and 11 NTRK rearrangements were found, all with intact kinase domains, and in… (full text at CIViC)

PMID 32457407 · Chu et al., 2020 · Open in CIViC

In a retrospective study of 79 RCC patients treated with diverse rapalogs (mTOR inhibitors) inactivating TSC1 and TSC2-mutations and activating MTOR-mutations were significantly more common in respons… (full text at CIViC)

PMID 26831717 · Kwiatkowski et al., 2016 · Open in CIViC

In 5 patients with renal cell carcinoma who achieved durable disease control with mTOR inhibitors (median duration, 28 months), Custom target capture and ultradeep sequencing was used to identify alt… (full text at CIViC)

PMID 24622468 · Voss et al., 2014 · Open in CIViC

In a retrospective study of 79 RCC patients treated with diverse rapalogs (mTOR inhibitors) inactivating TSC1 and TSC2-mutations and activating MTOR-mutations were significantly more common in respons… (full text at CIViC)

PMID 26831717 · Kwiatkowski et al., 2016 · Open in CIViC

6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.

PMID 19040416 · Barletta et al., 2009 · Open in CIViC

TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.

PMID 23645741 · Kasai et al., 2013 · Open in CIViC

In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).

PMID 22422354 · Shen et al., 2012 · Open in CIViC

In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP. The patient attained a reduction in the target lesions by 14.2… (full text at CIViC)

PMID 25922291 · Le et al., 2015 · Open in CIViC